活动概览 | 晶云药物与您相约九月

首页>资源中心 >会议信息

活动概览 | 晶云药物与您相约九月

2025-09-04

九月启新，共探前沿。晶云药物将携创新技术，亮相九月多项海内外、线上线下行业会议活动，期待与行业各位同仁相约中国上海、美国波士顿以及费城，共话药物研发前沿议题。

行业会议

SIT 2025第七届小分子药物创新峰会

9/17-18 | 上海

请点击查阅详情 ↑

SIT 2025第七届小分子药物创新峰会将于2025年9月17-18日在上海盛大召开。此次大会将汇聚70多位业内顶尖的化学药物专家和1000+行业同仁，聚焦减重药物的突破性研究、多肽药物的最新进展以及不可成药靶点的攻克。

晶云药物将在A6展位期待各位莅临，同时晶云星空（晶云药物CDMO事业部）CEO马德成博士将围绕《PROTAC口服制剂的研发策略》为大家带来技术分享。

时间：2025年9月17-18日

地点：上海圣诺亚皇冠假日酒店 3楼亚美厅

展位：A6

2025年9月17日

14:30-15:00

《PROTAC口服制剂的研发策略》

介绍开发PROTAC口服制剂的挑战，包括如何增加溶解度，渗透性和提高生物利用度等，并用可行性研究和IND开发实际案例进行详尽的分析

马德成博士

晶云星空（CDMO事业部）CEO

拥有25年跨国药企的制剂研发及外包管理经验，曾在默克美国和默沙东中国工作22年。专注于固体口服制剂的开发，分析及临床供应。主导、参与或支持超过30个新药研发项目，其中5个实现商业化。

学历背景：清华大学高分子材料与化学工程学士，美国塔夫茨大学化学工程硕士，美国里海大学化学工程博士。

海外活动

Formulation Forum Webinar

Applying PBPK and PBBM Across R&D: From Early Insights to Formulation

9/24 ET | Online

Date/Time: September 24, Wednesday, 2:00-3:00 PM

Presenter:

Deanna Mudie, Ph.D.

Senior Principal Scientist of PBPK R&D

Simulations Plus

Abstract:

Physiologically based pharmacokinetic and biopharmaceutics modeling (PBPK/PBBM) are transforming drug development by reducing reliance on time-consuming and costly in vivo studies and accelerating decision-making. These modeling approaches provide a mechanistic framework to support drug development from discovery through formulation. In this webinar, Deanna Mudie, Senior Principal Scientist of PBPK R&D at Simulations Plus, will explain how high-throughput PBPK using ADMET Predictor^® can rapidly predict systemic exposure using in silico derived properties or minimal in vitro data, enabling more informed compound selection and reducing the need for extensive preclinical testing. She’ll also cover how in later stages, PBBM using GastroPlus^® integrates drug and formulation properties with gastrointestinal physiology to simulate in vivo performance — supporting formulation optimization, food-effect prediction, and the development of clinically relevant dissolution specifications. Whether you're a modeler, formulation scientist, or development strategist, this session will provide real world case studies demonstrating how integrating PBPK and PBBM across the drug development continuum can enhance productivity, reduce in vivo study requirements, and enable smarter, faster decisions.

Scroll to read the full abstract

Register Link:

https://go.crystalpharmatech.com/crystal-pharmatech-formulation-forum/2025-ep11-registration

Simulation plus Webinar

Can you spare 25mg? Optimizing Benchwork and Computational Approaches to Assess CMC Success

9/11 ET | Online

Date/Time: September 11, 8:00 AM Pacific / 11:00 AM Eastern

Presenter:

Robert Wenslow, Ph.D.
Co-Founder and CBO
Crystal Pharmatech
Moderator:
Andrew Mueller
Director, Business Development
Simulations Plus

Summary

Drug discovery scientists often believe gram scale quantities of active pharmaceutical ingredient (API) are required to determine chemistry, manufacturing, and controls (CMC) properties like solubility, oral absorption, salt selection, and formulation strategy. But in this webinar, Crystal Pharmatech Co-Founder and Chief Business Officer, Robert Wenslow will present advanced computational approaches and a focused lab component to provide you with development risks with only 25mg of material. This allows developability to truly mainstream into late lead optimization and significantly enhance the probability of success (POS) for Phase I candidates.

Scroll to read the full summary

Attendees will have the chance to get their questions answered during the live Q&A moderated by Simulations Plus Director, Business Development, Andrew Mueller. Don’t miss out on this opportunity to learn from an industry expert—register now.

Register Link:

https://www.simulations-plus.com/events/can-you-spare-25mg-optimizing-benchwork-and-computational-approaches-to-assess-cmc-success/

American Drug Delivery & Formulation Summit

9/15-16 ET | Boston, MA

Date: September 15-16

Location: The Westin Copley Place, Boston

Attendee:

Ye Gu, Ph.D.
Co-founder, CTO and Head of Business Development
Crystal Bio Solutions (a member of Crystal Pharmatech)
Yongqiang Li, Ph.D.
CEO of Canada CDMO BU
Candoo Pharmatech
Dragutin Knezic, Ph.D.
Business Development Director
Crystal Pharmatech

Booth: 30

Presentation: Self-emulsifying Drug Delivery System: Formulation Development and Characterization of a Lipophilic Compound
Poster: Formulation Development of PLGA-Based Long-Acting Injectable In-situ Depot for Peptide Delivery